Skip to main content

Diabetes complications and comorbidities: Nephropathy

medwireNews

09-04-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

06-22-2023 | Cardiovascular outcomes | News

Finerenone modifies CKD-associated CV risk in albuminuric type 2 diabetes

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

05-26-2023 | Type 2 diabetes | News

Common antidiabetic add-on therapies offer similar renal outcomes

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

02-24-2023 | Risk factors | News

Mortality risk factors vary by age in type 2 diabetes

Hypertension has the largest impact on mortality risk in younger people with type 2 diabetes, whereas chronic kidney disease is a greater threat for older people, shows a population-based study.

01-17-2023 | Lifestyle interventions | News

Healthy lifestyle wards off type 2 diabetes microvascular complications

Real-world data from the UK Biobank show the value of a healthy lifestyle in people with type 2 diabetes hoping to avoid microvascular complications.

12-08-2022 | Dapagliflozin | News

Dapagliflozin may cut hospitalization risk in CKD

A post-hoc analysis of DAPA-CKD indicates that people taking dapagliflozin have a reduced risk for hospitalization, for causes not limited to cardiac or renal.

12-02-2022 | Nephropathy | News

CKD strongest determinant of post-MI prognosis in type 1 diabetes

The presence of chronic kidney disease has a large impact on the likelihood of people with type 1 diabetes dying after a myocardial infarction, show findings from the FinnDiane Study.

Close up of urinalysis with reagent strips

11-10-2022 | Nephropathy | News

‘Strong justification’ for individualized albuminuria screening in type 1 diabetes

Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.

Human kidney cross section

11-08-2022 | SGLT2 inhibitors | News

Meta-analysis backs SGLT2 inhibitors for kidney disease

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

11-04-2022 | Empagliflozin | News | Article

EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

09-22-2022 | EASD 2022 | Conference coverage | News

Microalbuminuria in pregnancy forecasts adverse outcomes

Women with type 1 diabetes who have microalbuminuria at the time of pregnancy have an increased risk for adverse pregnancy outcomes in the short term and for diabetes complications in the long term, shows research.

09-09-2022 | COVID-19 | News

Microvascular complications linked to COVID-19 mortality risk in people with type 2 diabetes

Study findings suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

08-18-2022 | Finerenone | News

Finerenone benefits independent of SGLT2 inhibitor use

Pooled analysis of FIDELIO-DKD and FIGARO-DKD suggests that people with type 2 diabetes and chronic kidney disease benefit from finerenone irrespective of whether they are also using an SGLT2 inhibitor.

07-07-2022 | Risk factors | News

Smoking ‘important risk factor’ for albuminuria in people with prediabetes

Smoking is associated with an increased risk for albuminuria in both people with prediabetes and those with diabetes, but quitting may not immediately circumvent this risk, researchers report.

06-21-2022 | Nephropathy | News

Real-world data confirm SGLT2 inhibitor renoprotection in type 2 diabetes

People with type 2 diabetes have a lower risk for chronic kidney disease progression and death when using SGLT2 inhibitors than when given DPP-4 inhibitors, real-world study data show.

06-08-2022 | ADA 2022 | Conference coverage | News

CKD and type 2 diabetes combined conveys greatest vascular risk in people with CVD

Individuals with cardiovascular disease who also have both chronic kidney disease and type 2 diabetes have a high risk for major cardiovascular events, shows research. 

Guidelines

06-07-2022 | ADA 2022 | Conference coverage | News

​​​​​​​ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

06-05-2022 | ADA 2022 | Conference coverage | News

Renal benefits of tirzepatide revealed

Tirzepatide may have a renoprotective effect in people with type 2 diabetes and high vascular risk, shows a prespecified analysis of SURPASS-4.

X-ray of fractured forearm shaft of radius and ulnar bone on red mark

05-24-2022 | Bone health | News

Poor glycemic control, kidney disease linked to bone fragility in type 1 diabetes

Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.

3d rendered medically accurate illustration of the human kidneys

05-06-2022 | Nephropathy | News

Renal prognosis improvements stalled in type 1 diabetes

The risk for kidney disease has fallen for people diagnosed with type 1 diabetes in more recent decades, but is still substantial and has stopped decreasing, study results suggest.